|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||26.41 / 80.67|
Medivation's (MDVN) stock rating was cut by several firms on Tuesday morning after the company agreed to be acquired by Pfizer (PFE) for $14 billion yesterday.
Earnings season is far from over, Cramer says, and the Fed chief gives a major speech Friday.
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of...
Wall Street will get more clues on the Fed's rate hike plans later this week, but uncertainty over what they might be led to jittery trading on Monday.
Stocks fluctuate Monday afternoon as a selloff in crude oil hits the energy sector and Federal Reserve speeches at the end of the week leave investors wary.
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Medivation, Inc.
Shareholders of the oncology drug maker ought to be satisfied with the auction's conclusion.
Pfizer's $14 billion acquisition of Medivation is a strong purchase, according to Jim Cramer, who now wonders what Sanofi will do next.
Stocks fluctuate on Monday as doubts over a production freeze agreement from major oil-producing countries snapped crude oil's recent rally.
Rigrodsky & Long, P.A.
PFE is trading up on the announcement, and the deal should add to earnings in 2017.
Overall, this is still a good environment for stock picking.
The deal is 'very healthy' for the biopharma group, according to TheStreet's Jim Cramer.
Pfizer confirmed its $14 billion acquisition of cancer drugmaker Medivation on Monday.
Stock futures move lower on Monday as doubts over a production freeze agreement from major oil-producing countries leave crude oil in the lurch.
Pfizer agrees to acquire Medivation while Citi puts Foot Locker and Under Armour on the back-to-school shopping list.
A potential blockbuster drug deal is reportedly in the works.
Pfizer finalizes a deal to buy cancer drugmaker Medivation; ChemChina gets U.S. approval for its takeover of Syngenta; Viacom CEO Philippe Dauman is ousted.
Acquiring Medivation will strengthen Pfizer's oncology franchise, which has lost ground in recent years to some Big Pharma competitors.
Earlier this month the two major pharmacy benefit managers, CVS Caremark CVS and Express Scripts ESRX released lists of drugs they will no longer cover in 2017.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AOSL, ARES, BREW, CHTR, FSIC, GBDC, IPAR, LUK, LUNA, NRCIA, ODP, OLED, PIP, STRL, VIPS Downgrades: BCRH, CBNK, DF, HALL, MDVN, MYGN, NMR, NYRT, SGU, TCRD, TEO Initiations: APPF, GLPI, SPNE, TDOC Read on to get TheStreet Quant Ratings' detailed report:
Here are Wednesday's top research calls, including upgrades for Coach and Yelp, and downgrades for SunPower and Wayfair.
Medivation (MDVN) stock was down in after-hours trading after the company posted lower-than-expected second quarter revenues.
The beaten-down biotech sector is making an impressive comeback. The sector seems to be rebounding after tumbling by more than 40%.
The sector seems to be rebounding after tumbling by more than 40%.